Pioglitazone in addition to metformin improves erythrocyte deformability in patients with Type 2 diabetes mellitus

Clinical Science

Volumn 119, Issue 8, 2010, Pages 345-351

  Forst, Thomas ^a   Weber, Matthias M ^a   Löbig, Mirjam ^a   Lehmann, Ute ^b   Müller, Jürgen ^c   Hohberg, Cloth ^a   Friedrich, Christiane ^a   Fuchs, Winfried ^b   Pfützner, Andreas ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Takeda Pharma GmbH   (Germany)

^c acromion GmbH   (Germany)

Author keywords

Adiponectin; Erythrocyte deformability; Insulin resistance; Metformin; Sulfonylurea; Thiazolidinedione; Type 2 diabetes mellitus

Indexed keywords

ADIPONECTIN; GLIMEPIRIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; METFORMIN; PIOGLITAZONE; PROINSULIN;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; DRUG MECHANISM; ERYTHROCYTE DEFORMABILITY; FEMALE; HEMATOCRIT; HUMAN; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; ERYTHROCYTE DEFORMABILITY; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; STRESS, MECHANICAL; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 77956363203     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20100161     Document Type: Article

References (51)

1. Marcinkowska-Gapinska, A. and Kowal, P. (2006) Blood fluidity and thermography in patients with diabetes mellitus and coronary artery disease in comparison to healthy subjects. Clin. Hemorheol. Microcirc. 35, 473-479
2. Koltai, K., Feher, G., Kesmarky, G., Keszthelyi, Z., Czopf, L. and Toth, K. (2006) The effect of blood glucose levels on hemorheological parameters, platelet activation and aggregation in oral glucose tolerance tests. Clin. Hemorheol. Microcirc. 35, 517-525
3. Zilberman-Kravits, D., Harman-Boehm, I., Shuster, T. and Meyerstein, N. (2006) Increased red cell aggregation is correlated with HbA1C and lipid levels in type 1 but not type 2 diabetes. Clin. Hemorheol. Microcirc. 35, 463-471
4. Hach, T., Forst, T., Kunt, T., Ekberg, K., Pfutzner, A. and Wahren, J. (2008) C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients. Exp. Diabetes Res. 2008, 730594
5. Brown, C. D., Ghali, H. S., Zhao, Z., Thomas, L. L. and Friedman, E. A. (2005) Association of reduced red blood cell deformability and diabetic nephropathy. Kidney Int. 67, 295-300
6. Garnier, M., Attali, J. R., Valensi, P., Delatour-Hanss, E., Gaudey, F. and Koutsouris, D. (1990) Erythrocyte deformability in diabetes and erythrocyte membrane lipid composition. Metab. Clin. Exp. 39, 794-798
7. Shin, S., Ku, Y. H., Ho, J. X., Kim, Y. K., Suh, J. S. and Singh, M. (2007) Progressive impairment of erythrocyte deformability as indicator of microangiopathy in type 2 diabetes mellitus. Clin. Hemorheol. Microcirc. 36, 253-261
8. Linderkamp, O., Ruef, P., Zilow, E. P. and Hoffmann, G. F. (1999) Impaired deformability of erythrocytes and neutrophils in children with newly diagnosed insulin-dependent diabetes mellitus. Int. J. Obes. Relat. Metab. Disord. 42, 865-869
9. Le Devehat, C., Khodabandehlou, T. and Vimeux, M. (1994) Relationship between hemorheological and microcirculatory abnormalities in diabetes mellitus. Diabetes Metab. 20, 401-404
10. Zimny, S., Dessel, F., Ehren, M., Pfohl, M. and Schatz, H. (2001) Early detection of microcirculatory impairment in diabetic patients with foot at risk. Diabetes Care 24, 1810-1814 (Pubitemid 33716487)
11. Cicco, G. and Pirrelli, A. (1999) Red blood cell (RBC) deformability, RBC aggregability and tissue oxygenation in hypertension. Clin. Hemorheol. Microcirc. 21, 169-177
12. Chmiel, B. and Cierpka, L. (2003) Organ preservation solutions impair deformability of erythrocytes in vitro. Transplant. Proc. 35, 2163-2164
13. Balletshofer, B. M., Rittig, K., Enderle, M. D. et al. (2000) Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 101, 1780-1784 (Pubitemid 30213098)
14. Nazzaro, P., Vulpis, V., Schirosi, G., Serio, G., Battista, L., Lucivero, V., Livrea, P. and Federico, F. (2008) Microvascular impairment is associated with insulin resistance in euglycemic mild hypertensives. Am. J. Hypertens. 21, 432-437
15. Perez-Martin, A., Dumortier, M., Pierrisnard, E., Raynaud, E., Mercier, J. and Brun, J. F. (2001) Multivariate analysis of relationships between insulin sensitivity and blood rheology: is plasma viscosity a marker of insulin resistance? Clin. Hemorheol. Microcirc. 25, 91-103
16. Moan, A., Nordby, G., Os, I., Birkeland, K. I. and Kjeldsen, S. E. (1994) Relationship between hemorrheologic factors and insulin sensitivity in healthy young men. Metab. Clin. Exp. 43, 423-427
17. Miyazaki, Y., Mahankali, A., Matsuda, M., Glass, L., Mahankali, S., Ferrannini, E., Cusi, K., Mandarino, L. J. and DeFronzo, R. A. (2001) Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24, 710-719
18. Maegawa, H., Nishio, Y., Nakao, K., Ugi, S., Maeda, K., Uzu, T. and Kashiwagi, A. (2007) Short-term low-dosage pioglitazone treatment improves vascular dysfunction in patients with type 2 diabetes. Endocr. J. 54, 613-618 (Pubitemid 47414611)
19. Forst, T., Lubben, G., Hohberg, C., Kann, P., Sachara, C., Gottschall, V., Friedrich, C., Rosskopf, R. and Pfützner, A. (2005) Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2. Microcirculation 12, 543-550 (Pubitemid 41632173)
20. Horio, T., Suzuki, M., Takamisawa, I., Suzuki, K., Hiuge, A., Yoshimasa, Y. and Kawano, Y. (2005) Pioglitazone-induced insulin sensitization improves vascular endothelial function in nondiabetic patients with essential hypertension. Am. J. Hypertens. 18, 1626-1630
21. Papathanassiou, K., Naka, K. K., Kazakos, N., Kanioglou, C., Makriyiannis, D., Pappas, K., Katsouras, C. S., Liveris, K., Kolettis, T., Tsatsoulis, A. and Michalis, L. K. (2009) Pioglitazone vs glimepiride: differential effects on vascular endothelial function in patients with type 2 diabetes. Atherosclerosis 205, 221-226
22. Forst, T., Pfutzner, A., Lubben, G., Weber, M., Marx, N., Karagiannis, E., Koehler, C., Baurecht, W., Hohberg, C. and Hanefeld, M. (2007) Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk: the PIOSTAT Study. Metab. Clin. Exp. 56, 491-496
23. Forst, T., Karagiannis, E., Lubben, G., Hohberg, C., Schöndorf, T., Dikta, G., Drexler, M., Morcos, M., Dänschel, W., Borchert, M. and Pfützner, A. (2008) Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease. Atherosclerosis 197, 311-317 (Pubitemid 351273253)
24. Mazzone, T., Meyer, P. M., Feinstein, S. B., Davidson, M. H., Kondos, G. T., D'Agostino, Sr, R. B., Perez, A., Provost, J.C. and Haffner, S.M. (2006) Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA, J. Am. Med. Assoc. 296, 2572-2581 (Pubitemid 44903861)
25. Nissen, S. E., Nicholls, S. J., Wolski, K., Nesto, R., Kupfer, S., Perez, A., Jure, H., De Larochellière, R., Staniloae, C. S., Mavromatis, K. et al. (2008) Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA, J. Am. Med. Assoc. 299, 1561-1573 (Pubitemid 351482795)
26. Evans, J. M., Ogston, S. A., Emslie-Smith, A. and Morris, A. D. (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Int. J. Obes. Relat. Metab. Disord. 49, 930-936
27. Pfutzner, A., Standl, E., Hohberg, C., Konrad, T., Strotmann, H. J., Lübben, G., Langenfeld, M. R., Schulze, J. and Forst, T. (2005) IRIS II study: intact proinsulin is confirmed as a highly specific indicator for insulin resistance in a large cross-sectional study design. Diabetes Technol. Ther. 7, 478-486
28. Rao, A. D., Kuhadiya, N., Reynolds, K. and Fonseca, V. A. (2008) Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care 31, 1672-1678
29. Kunt, T., Schneider, S., Pfutzner, A., Goitum, K., Engelbach, M., Schauf, B., Beyer, J. and Forst, T. (1999) The effect of human proinsulin C-peptide on erythrocyte deformability in patients with type 1 diabetes mellitus. Diabetologia 42, 465-471
30. Baskurt, O. K., Hardeman, M. R., Uyuklu, M., Ulker, P., Cengiz, M., Nemeth, N., Shin, S., Alexy, T. and Meiselman, H. J. (2009) Parameterization of red blood cell elongation index-shear stress curves obtained by ektacytometry. Scand. J. Clin. Lab. Invest. 69, 777-788
31. Parthasarathi, K. and Lipowsky, H. H. (1999) Capillary recruitment in response to tissue hypoxia and its dependence on red blood cell deformability. Am. J. Physiol. 277, H2145-H2157
32. Secomb, T. W. and Hsu, R. (1995) Red blood cell mechanics and functional capillary density. Int. J. Microcirc. Clin. Exp. 15, 250-254
33. Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D. et al. (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events): a randomised controlled trial. Lancet 366, 1279-1289
34. Erdmann, E., Dormandy, J. A., Charbonnel, B., Massi-Benedetti, M., Moules, I. K. and Skene, A. M. (2007) The effect of pioglitazone on recurrent myocardial infarction in 2, 445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J. Am. Coll. Cardiol. 49, 1772-1780
35. Pfutzner, A., Hohberg, C., Lubben, G., Pahler, S., Pfützner, A. H., Kann, P. and Forst, T. (2005) Pioneer study: PPARγ activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control. Horm. Metab. Res. 37, 510-515
36. Langenfeld, M. R., Forst, T., Hohberg, C., Kann, P., Lübben, G., Konrad, T., Füllert, S. D., Sachara, C. and Pfützner, A. (2005) Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 111, 2525-2531 (Pubitemid 40696142)
37. Lam, K. S. and Xu, A. (2005) Adiponectin: protection of the endothelium. Curr. Diab. Rep. 5, 254-259
38. Ouchi, N., Ohishi, M., Kihara, S., Funahashi, T., Nakamura, T., Nagaretani, H., Kumada, M., Ohashi, K., Okamoto, Y., Nishizawa, H. et al. (2003) Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 42, 231-234
39. Sakuta, H., Suzuki, T., Yasuda, H. and Ito, T. (2005) Adiponectin levels and cardiovascular risk factors in Japanese men with type 2 diabetes. Endocr. J. 52, 241-244 (Pubitemid 40745714)
40. Kumada, M., Kihara, S., Sumitsuji, S., Kawamoto, T., Matsumoto, S., Ouchi, N., Arita, Y., Okamoto, Y., Shimomura, I., Hiraoka, H. et al. (2003) Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler. Thromb. Vasc. Biol. 23, 85-89
41. Forst, T., Hohberg, C., Fuellert, S. D., Lübben, G., Konrad, T., Löbig, M., Weber, M. M., Sachara, C., Gottschall, V. and Pfützner, A. (2005) Pharmacological PPARγ stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes. Horm. Metab. Res. 37, 521-527
42. Tsuda, K. and Nishio, I. (2003) Membrane fluidity and hypertension. Am. J. Hypertens. 16, 259-261
43. Zicha, J., Kunes, J. and Devynck, M. A. (1999) Abnormalities of membrane function and lipid metabolism in hypertension: a review. Am. J. Hypertens. 12, 315-331
44. Tsuda, K. (2006) Adiponectin and membrane fluidity of erythrocytes in normotensive and hypertensive men. Obesity 14, 1505-1510
45. Chen, H., Montagnani, M., Funahashi, T., Shimomura, I. and Quon, M. J. (2003) Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J. Biol. Chem. 278, 45021-45026
46. Mesquita, R., Picarra, B., Saldanha, C. and Martins e Silva, C. (2002) Nitric oxide effects on human erythrocytes structural and functional properties: an in vitro study. Clin. Hemorheol. Microcirc. 27, 137-147
47. Bateman, R. M., Jagger, J. E., Sharpe, M. D., Ellsworth, M. L., Mehta, S. and Ellis, C. G. (2001) Erythrocyte deformability is a nitric oxide-mediated factor in decreased capillary density during sepsis. Am. J. Physiol. Heart Circ. Physiol. 280, H2848-H2856
48. Froom, P. (2000) Blood viscosity and the risk of death from coronary heart disease. Eur. Heart J. 21, 513-514
49. Natali, A., Toschi, E., Baldeweg, S., Casolaro, A., Baldi, S., Sironi, A. M., Yudkin, J. S. and Ferrannini, E. (2005) Haematocrit, type 2 diabetes, and endothelium-dependent vasodilatation of resistance vessels. Eur. Heart J. 26, 464-471
50. Berria, R., Glass, L., Mahankali, A., Miyazaki, Y., Monroy, A., De Filippis, E., Cusi, K., Cersosimo, E., Defronzo, R. A. and Gastaldelli, A. (2007) Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus. Clin. Pharmacol. Ther. 82, 275-281
51. Belcher, G., Lambert, C., Edwards, G., Urquhart, R. and Matthews, D. R. (2005) Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes. Diabetes Res. Clin. Pract. 70, 53-62